Targeted Medical Pharma Reports New Data on Red Blood Cell Stimulating Formulation
3/4/2013 9:59:58 AM
LOS ANGELES--(BUSINESS WIRE)--Targeted Medical Pharma, Inc. (OTCQB: TRGM) (OTCBB: TRGM), a biopharmaceutical company that develops and distributes prescription medical foods to physicians and pharmacies, today unveiled new results from an open label study of its oral amino acid-based erythrocyte stimulating system (ESS) for the treatment of chronic anemia. The company’s ESS system is designed to stimulate progenitor stem cells in the bone marrow. Subjects in the study diagnosed with mild to moderate anemia were administered 1800mg of the company’s oral formulation daily for seven days. Each subject underwent weekly blood sampling, including hemoglobin, hematocrit and reticulocyte count for four weeks from the initial dosing, and once more 45 days following the initial dose. Hemoglobin increased an average of 11.39 percent from baseline measurement to 45 days. The average baseline hemoglobin measurement was 10.08 and 11.21 after 45 days with a similar increase in reticulocyte count (p<0.01).
comments powered by